Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 101 to 150 of 294

TitleTypeExpected publication date
Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID6302]Technology appraisal guidance
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]Technology appraisal guidance
Gefapixant for treating refractory or unexplained chronic cough [ID3789]Technology appraisal guidanceTBC
Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]Technology appraisal guidanceTBC
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over ID6323Technology appraisal guidanceTBC
Glaucoma - lerdelimumab (CAT-152) [ID383]Technology appraisal guidanceTBC
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma ID6202Technology appraisal guidanceTBC
Guselkumab for previously treated moderately to severely active Crohn's disease ID6238Technology appraisal guidanceTBC
Guselkumab for treating moderately to severely active ulcerative colitis ID6237Technology appraisal guidanceTBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]Technology appraisal guidanceTBC
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease ID6343Technology appraisal guidanceTBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]Technology appraisal guidanceTBC
Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID1251]Technology appraisal guidanceTBC
Ibrutinib for untreated mantle cell lymphoma [ID1221]Technology appraisal guidanceTBC
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]Technology appraisal guidanceTBC
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]Technology appraisal guidanceTBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373Technology appraisal guidanceTBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]Technology appraisal guidanceTBC
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]Technology appraisal guidanceTBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]Technology appraisal guidanceTBC
Iptacopan for treating paroxysmal nocturnal haemoglobinuria [ID6176]Technology appraisal guidance
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]Technology appraisal guidance
Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [ID3834]Technology appraisal guidanceTBC
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]Technology appraisal guidance
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]Technology appraisal guidanceTBC
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]Technology appraisal guidanceTBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]Technology appraisal guidanceTBC
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over [ID4025]Technology appraisal guidanceTBC
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]Technology appraisal guidanceTBC
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]Technology appraisal guidanceTBC
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]Technology appraisal guidanceTBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]Technology appraisal guidanceTBC
Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166]Technology appraisal guidanceTBC
Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]Technology appraisal guidanceTBC
Linzagolix for treating pain caused by endometriosis [ID6357]Technology appraisal guidanceTBC
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma [ID1444]Technology appraisal guidanceTBC
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]Technology appraisal guidanceTBC
Lisocabtagene maraleucel for treating relapsed or refractory diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B after first-line chemotherapy [ID3887]Technology appraisal guidance
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]Technology appraisal guidanceTBC
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]Technology appraisal guidanceTBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]Technology appraisal guidanceTBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340Technology appraisal guidanceTBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]Technology appraisal guidanceTBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]Technology appraisal guidanceTBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]Technology appraisal guidanceTBC
Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]Technology appraisal guidanceTBC
Marstacimab for treating severe haemophilia A or moderately severe to severe haemophilia B in people 12 years and over [ID6342]Technology appraisal guidanceTBC
Masitinib with riluzole for treating amyotrophic lateral sclerosis ID6257Technology appraisal guidanceTBC
Melanoma (metastatic) - talimogene laherparepvec [ID508]Technology appraisal guidance
Mirikizumab for treating moderately to severely active Crohn's disease ID6244Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All